NEPH (Nephros) Total Equity: $10.70 Mil (As of Mar. 2026)


NEPH Nephros Inc NEPH
63 GF Score
Price $3.40
GF Value $2.88
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nephros Total Equity?

Nephros NEPH +0.89% 63 Total Equity is $10.70 Mil as of Mar. 2026. GuruFocus rates NEPH with a GF Score™ of 63/100 and a GF Value™ of $2.88 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Nephros's total equity for the quarter that ended in Mar. 2026 was $10.70 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Nephros Total Equity Historical Data

* Premium members only.

The historical data trend for Nephros's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nephros Total Equity Chart

Nephros Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.75 8.88 8.36 8.59 10.20

Nephros Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.29 9.60 10.01 10.20 10.70
NEPH
63GF Score
Nephros Inc NEPH
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nephros Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Nephros's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=13.641-3.439
=10.20

Nephros's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=13.794-3.093
=10.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $10.70 Mil mean?
Nephros (NEPH) has a Total Equity of $10.70 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Nephros and its competitors.
Is Nephros' Total Equity too high?
Nephros' current Total Equity is $10.70 Mil. Overall, Nephros has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' Total Equity compare to MLSS and RGNT?
Nephros' Total Equity of $10.70 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Nephros and its competitors. Nephros's current Total Equity is $10.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.88, compared to a current price of $3.40 — trading 18.1% above its estimated fair value. The current Total Equity is $10.70 Mil. Nephros' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Nephros (NEPH), the current Total Equity is $10.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nephros (NEPH) Overvalued in 2026?

Based on GuruFocus' analysis, Nephros stock appears to be overvalued. The current stock price of $3.40 is trading 18.1% above its estimated GF Value™ of $2.88. GuruFocus considers Nephros to be Modestly Overvalued.

Key valuation signals for NEPH:

  • Total Equity: $10.70 Mil
  • GF Value™: $2.88 vs. price of $3.40 (18.1% above fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nephros Business Description

Other Exchanges NPJP:Germany
Address 380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
63GF Score

Get the complete analysis for NEPH

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.40
Price
$2.88
GF Value